PRA, a leading Clinical Research Organization, announces the opening of a second office in China to accommodate its continued expansion in China and the Asia Pacific region. PRA established its first China office in Shanghai in 2005. PRA’s new facility, located in the central business district of Beijing, is designed to enhance the company's local project teams’ ability to meet the growing demand for clinical drug development programs and co-locate with key clients in Beijing.
“As the demand for clinical sites in Asia increase, we continually strive to strengthen our existing operations in China and the Asia Pacific region,” said Helen Neal, Regional Director – Clinical Operations, Asia Pacific, Middle East, and North Africa. “By adding more professional staff and locations, we can give our clients greater access to these critical markets and geography. In addition to our expansion in China, we continue to increase our presence into new and emerging Southeast Asian regions for access to patients and resources.”
“We are very excited about our continued expansion into China,” said Kent Thoelke, Executive Vice President, Scientific & Medical Affairs. “In order for global drug development to continue successfully, the need to access patients at high-quality ICH/GCP sites in emerging regions like China is critical. PRA’s expansion in this market gives us the ability to bring exciting new clinical trials to a much broader market in China, while providing even greater patient access to our clients and sponsor companies.”
PRA has been operating in China for over 10 years and also has an office in Hong Kong. Additional Asia Pacific locations include South Korea, Taiwan, Thailand, Singapore, Australia, New Zealand, and India.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.